Cargando…

Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory

INTRODUCTION: Simeprevir, a new oral NS3/4A protease inhibitor, was recently approved by the FDA and the EMA for the treatment of patients with chronic HCV genotype 1, 4, 5 and 6 infection l. It has been recommended in the 2014 UK Consensus Guidelines as a possible treatment of previously untreated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ehret, Robert, Neifer, Stefan, Walter, Hauke, Baumgarten, Axel, Obermeier, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P209
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225327/ https://www.ncbi.nlm.nih.gov/pubmed/25397486 http://dx.doi.org/10.7448/IAS.17.4.19741

Ejemplares similares

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014)

Rôle de la tomodensitométrie thoracique dans le diagnostic de l’infection respiratoire à COVID-19
por: Madi, W., et al.
Publicado: (2022)

Resistance remains a problem in treatment failure
por: Obermeier, Martin, et al.
Publicado: (2014)

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapy
por: Carganico, Andreas, et al.
Publicado: (2014)

Acute hepatitis C virus (HCV) infection in the setting of HIV coinfection: a single-centre 10-year follow-up
por: Ingiliz, Patrick, et al.
Publicado: (2014)

Analysis of hepatitis non-treatment causes in a cohort of HCV and HCV/HIV infected patients
por: Pereira, Karen, et al.
Publicado: (2014)

HCV triple therapy in co-infection HIV/HCV is not associated with a different risk of developing major depressive disorder
por: Fialho, Renata, et al.
Publicado: (2014)

Improve screening of HCV infection by targeting high prevalence aged groups: analysis of a cohort of HCV and HIV co-infected patients
por: Brogueira, Pedro, et al.
Publicado: (2014)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability
por: Dultz, Georg, et al.
Publicado: (2021)

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region
por: Torre, P., et al.
Publicado: (2022)

Effect of HIV infection-related factors on SVR rate in HCV treatment in HIV-infected patients
por: Kravchenko, Alexey, et al.
Publicado: (2014)

Alarming increase in tuberculosis and hepatitis C virus (HCV) among HIV infected intravenous drug users
por: Oprea, Cristiana, et al.
Publicado: (2014)

Evaluation of the degree of liver fibrosis and genetical characteristics in HIV patients with spontaneous clearance of HCV in Cartagena, Spain
por: Jesús Vera Méndez, Francisco, et al.
Publicado: (2014)

Liver Fibrosis progression using Fibroscan in HIV/HCV coinfected patients with undetectable HIV viral load
por: Perez-Martinez, Laura, et al.
Publicado: (2014)

Hepatitis C (HCV) therapy for HCV mono-infected and HIV-HCV co-infected individuals living in Nepal
por: KC, Sudhamshu, et al.
Publicado: (2020)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

Monitoring renal function during combination therapy with telaprevir in HIV/HCV co-infected patients with advanced/fibrosis cirrhosis
por: Puzzolante, Cinzia, et al.
Publicado: (2014)

Incidence of recent HCV infection among persons seeking voluntary counselling and testing for HIV and sexually transmitted infections in Taiwan
por: Su, Yi-Ching, et al.
Publicado: (2014)

Plasmacytoid Dendritic cells (pDCs) in HIV-infected and HIV/HCV-co-infected patients receiving successful treatment
por: Khokhlova, Olga, et al.
Publicado: (2014)

Implementation of hcv screening in the 1969-1989 birth-cohort undergoing covid-19 vaccination: a pivotal study in Italy
por: D'Ambrosio, R., et al.
Publicado: (2022)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Risk of liver decompensation assessed in HIV/HCV co-infected individuals with advanced liver fibrosis: a faster countdown experience
por: Pedro Alves, Joao, et al.
Publicado: (2014)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis
por: Montes, Marisa, et al.
Publicado: (2014)

Immune Biomarker Differences and Changes Comparing HCV Mono-Infected, HIV/HCV Co-Infected, and HCV Spontaneously Cleared Patients
por: Kushner, Lauren E., et al.
Publicado: (2013)

Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug users
por: Jamalidoust, Marzieh, et al.
Publicado: (2017)

Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283
por: Demetriou, Victoria L, et al.
Publicado: (2010)

Direct Binding of Ledipasvir to HCV NS5A: Mechanism of Resistance to an HCV Antiviral Agent
por: Kwon, Hyock Joo, et al.
Publicado: (2015)

Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study
por: Minguez, Carlos, et al.
Publicado: (2014)

Molecular surveillance of HCV mono-infection and HCV-HBV co-infection in symptomatic population at Hyderabad, Pakistan
por: Patoli, Bushra B, et al.
Publicado: (2018)

Detection of Parvovirus 4 in Iranian patients with HBV, HCV, HIV mono-infection, HIV and HCV co-infection
por: Rastegarpouyani, Hosna, et al.
Publicado: (2018)

Identification of NS2 determinants stimulating intrinsic HCV NS2 protease activity
por: Isken, Olaf, et al.
Publicado: (2022)

The Future of HCV Therapy: NS4B as an Antiviral Target
por: Dvory-Sobol, Hadas, et al.
Publicado: (2010)

Peg-interferon Plus Ribavirin Combination Therapy in HCV Mono-infected and HCV/HIV Co-infected Patients in Iran
por: Hesamizadeh, Khashayar, et al.
Publicado: (2019)

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
por: Bono, Valeria, et al.
Publicado: (2022)

Transcriptomic Assay of CD8(+) T Cells in Treatment-Naïve HIV, HCV-Mono-Infected and HIV/HCV-Co-Infected Chinese
por: Zhao, Jin, et al.
Publicado: (2012)

MicroRNA signature from extracellular vesicles of HCV/HIV co-infected individuals differs from HCV mono-infected
por: Cairoli, Victoria, et al.
Publicado: (2023)

Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors
por: Wiesmann, F., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_mnabjfeecid767bda0mel5m0tp